MA32394B1 - Composes pegyles d'insuline lispro - Google Patents

Composes pegyles d'insuline lispro

Info

Publication number
MA32394B1
MA32394B1 MA33425A MA33425A MA32394B1 MA 32394 B1 MA32394 B1 MA 32394B1 MA 33425 A MA33425 A MA 33425A MA 33425 A MA33425 A MA 33425A MA 32394 B1 MA32394 B1 MA 32394B1
Authority
MA
Morocco
Prior art keywords
relates
antiviral compounds
insulin lyspro
lyspro
insulin
Prior art date
Application number
MA33425A
Other languages
Arabic (ar)
English (en)
Inventor
John Michael Beals
Gordon Butler Cutler
Brandon Doyle
Ryan John Hansen
Shun Li
Shahriar Shirani
Lianshan Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41110836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32394(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32394B1 publication Critical patent/MA32394B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur le domaine du diabète. Plus particulièrement, l'invention porte sur des composés insuliniques lispro pégylés qui sont pégylés par un poly(éthylène glycol) de masse moléculaire élevée, sont très solubles à un pH physiologique, ont une durée d'action étendue et sont caractérisés par des rapports maximum-minimum pharmacocinétiques, pharmacodynamiques et/ou d'activité inférieurs à 2. L'invention porte également sur des procédés consistant à fournir de telles molécules, sur des compositions pharmaceutiques les contenant et sur leurs utilisations thérapeutiques.
MA33425A 2008-06-13 2010-12-13 Composes pegyles d'insuline lispro MA32394B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6128108P 2008-06-13 2008-06-13
US12139408P 2008-12-10 2008-12-10
PCT/US2009/046704 WO2009152128A1 (fr) 2008-06-13 2009-06-09 Composés insuliniques lispro pégylés

Publications (1)

Publication Number Publication Date
MA32394B1 true MA32394B1 (fr) 2011-06-01

Family

ID=41110836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33425A MA32394B1 (fr) 2008-06-13 2010-12-13 Composes pegyles d'insuline lispro

Country Status (33)

Country Link
US (3) US9050371B2 (fr)
EP (2) EP2288375B1 (fr)
JP (2) JP4890662B2 (fr)
KR (1) KR101238979B1 (fr)
CN (1) CN102065884B (fr)
AR (1) AR071990A1 (fr)
AT (1) ATE554786T1 (fr)
AU (1) AU2009257597B2 (fr)
BR (1) BRPI0915838A2 (fr)
CA (1) CA2727825C (fr)
CL (1) CL2009001340A1 (fr)
CO (1) CO6331292A2 (fr)
CY (2) CY1112977T1 (fr)
DK (2) DK2476430T3 (fr)
DO (1) DOP2010000379A (fr)
EA (1) EA028657B1 (fr)
EC (1) ECSP10010677A (fr)
ES (2) ES2473580T3 (fr)
HR (2) HRP20120397T1 (fr)
IL (1) IL209265A (fr)
JO (1) JO2932B1 (fr)
MA (1) MA32394B1 (fr)
MX (1) MX2010013837A (fr)
MY (1) MY158890A (fr)
NZ (1) NZ588997A (fr)
PE (2) PE20091960A1 (fr)
PL (2) PL2476430T3 (fr)
PT (2) PT2476430E (fr)
RS (1) RS52361B (fr)
SI (2) SI2476430T1 (fr)
TW (1) TWI451876B (fr)
WO (1) WO2009152128A1 (fr)
ZA (1) ZA201008174B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107069B1 (fr) * 2003-08-05 2013-01-16 Novo Nordisk A/S Nouveaux dérivés d'insuline
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
WO2009115469A1 (fr) 2008-03-18 2009-09-24 Novo Nordisk A/S Analogues de l'insuline acylés stabilisés vis-à-vis des protéases
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR20110085985A (ko) * 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
EP3409289B1 (fr) 2010-02-26 2020-09-30 Novo Nordisk A/S Compositions contenant un anticorps stable
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP6249773B2 (ja) * 2010-05-10 2017-12-20 ノヴォ ノルディスク アー／エス インスリン−亜鉛錯体の調製方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
CA2800348C (fr) * 2010-05-18 2020-07-21 Lena A. Basile Formulations d'il-12 pour la stimulation de l'hematopoiese
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA3140885A1 (fr) 2010-12-13 2012-06-21 Quiapeg Pharmaceuticals Ab Polymeres fonctionnalises
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9944688B2 (en) 2011-06-02 2018-04-17 Hanmi Science Co., Ltd. Non-peptidyl polymer-insulin multimer and method for producing the same
WO2012174478A2 (fr) * 2011-06-17 2012-12-20 Halozyme, Inc. Formulations stables d'enzyme de dégradation d'hyaluronane
WO2013021143A1 (fr) * 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2763701B1 (fr) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Nucléosides, nucléotides et acides nucléiques modifiés, et leurs utilisations
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR090843A1 (es) 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA2876315C (fr) 2012-06-12 2021-05-25 Marek Kwiatkowski Conjugues de molecules biologiquement actives a des polymeres fonctionnalises
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
ES2670969T3 (es) * 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN105092490B (zh) * 2014-05-04 2019-08-09 重庆派金生物科技有限公司 人胰岛素及类似物或偶联物体外生物活性测定方法
WO2016065052A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR107560A1 (es) 2016-02-24 2018-05-09 Lilly Co Eli Compuesto que disminuye la glucosa en la sangre
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
WO2018153506A1 (fr) * 2017-02-22 2018-08-30 Adocia Composition d'insuline à action rapide contenant un sel d'acide citrique
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
KR20190140048A (ko) * 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
WO2018232357A1 (fr) 2017-06-15 2018-12-20 Modernatx, Inc. Formulations d'arn
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
FR3084585B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
EP3849660A1 (fr) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Conjugués de glp-1 libérables
WO2020061457A1 (fr) 2018-09-20 2020-03-26 Modernatx, Inc. Préparation de nanoparticules lipidiques et leurs méthodes d'administration
WO2020186247A1 (fr) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions et méthodes pour favoriser la viabilité des îlots et améliorer la sécrétion d'insuline
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
EP4072577A4 (fr) * 2019-12-13 2024-02-14 The Board of Trustees of the Leland Stanford Junior University Formulations d'insuline monomères stables activées par pégylation supramoléculaire d'analogues d'insuline
CN113801236A (zh) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 一种赖脯胰岛素的制备方法
US20230025595A1 (en) * 2021-07-13 2023-01-26 America Great Health, a California Corporation Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
WO2023225534A1 (fr) 2022-05-18 2023-11-23 Protomer Technologies Inc. Composés contenant du bore aromatiques et analogues d'insuline associés
EP4593867A2 (fr) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Parathormone à action prolongée

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3880346T2 (de) 1987-02-25 1993-07-29 Novonordisk As Insulinderivate.
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
WO2001052937A1 (fr) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Systeme tampon melange pour la stabilisation de preparations pour polypeptides
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CA2447236A1 (fr) * 2001-05-21 2002-11-28 Nektar Therapeutics Administration par voie pulmonaire d'insuline chimiquement modifiee
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
CA2521784C (fr) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
BRPI0409322B8 (pt) * 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
EP1789434B1 (fr) * 2004-08-31 2013-11-20 Novo Nordisk A/S Utilisation de tris(hydroxymethyl)aminomethane pour la stabilisation de peptides, polypeptides et proteines
US20060045866A1 (en) 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US7199193B2 (en) 2004-09-28 2007-04-03 Dow Global Technologies, Inc. Polyethylene glycol compounds and process of making
CA2603630C (fr) * 2005-01-14 2015-06-09 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendines modifiees et utilisations correspondantes
WO2006079641A2 (fr) 2005-01-27 2006-08-03 Novo Nordisk A/S Derives d'insuline conjugues avec des polymeres ramifies structurellement bien definis
US7824919B2 (en) 2005-03-04 2010-11-02 Dr. Reddy's Laboratories Limited Method for analyzing activated polyethylene glycol compounds
JP2008533100A (ja) * 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
CN101166545B (zh) * 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物
EP2364735A3 (fr) * 2005-12-16 2012-04-11 Nektar Therapeutics Conjugé de GLP-1 et de PEG ramafié
JP5550338B2 (ja) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
WO2008084051A1 (fr) * 2007-01-12 2008-07-17 Novo Nordisk A/S Mélanges d'insuline pégylée et d'insuline à action rapide pour une administration pulmonaire
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物

Also Published As

Publication number Publication date
PT2288375E (pt) 2012-05-17
AR071990A1 (es) 2010-07-28
CY1115354T1 (el) 2017-01-04
EP2476430B1 (fr) 2014-05-14
CN102065884B (zh) 2014-11-05
ZA201008174B (en) 2012-04-25
KR101238979B1 (ko) 2013-03-05
HK1149713A1 (en) 2011-10-14
JP5336572B2 (ja) 2013-11-06
JO2932B1 (en) 2015-09-15
PL2288375T3 (pl) 2012-09-28
ATE554786T1 (de) 2012-05-15
RS52361B (sr) 2012-12-31
EP2288375A1 (fr) 2011-03-02
HRP20140480T1 (hr) 2014-07-04
CA2727825A1 (fr) 2009-12-17
US20110105392A1 (en) 2011-05-05
US20090312236A1 (en) 2009-12-17
SI2476430T1 (sl) 2014-07-31
EP2288375B1 (fr) 2012-04-25
EP2476430A1 (fr) 2012-07-18
PL2476430T3 (pl) 2014-09-30
DOP2010000379A (es) 2011-03-31
EA028657B1 (ru) 2017-12-29
CY1112977T1 (el) 2016-04-13
HK1170659A1 (en) 2013-03-08
SI2288375T1 (sl) 2012-07-31
KR20110017879A (ko) 2011-02-22
JP2011524357A (ja) 2011-09-01
CN102065884A (zh) 2011-05-18
US9050371B2 (en) 2015-06-09
AU2009257597A1 (en) 2009-12-17
PE20140974A1 (es) 2014-08-25
AU2009257597B2 (en) 2011-10-06
TW201010728A (en) 2010-03-16
ECSP10010677A (es) 2011-01-31
US20150297681A1 (en) 2015-10-22
EA201170020A1 (ru) 2011-10-31
PT2476430E (pt) 2014-07-25
IL209265A0 (en) 2011-01-31
IL209265A (en) 2014-08-31
CO6331292A2 (es) 2011-10-20
JP4890662B2 (ja) 2012-03-07
DK2476430T3 (da) 2014-06-02
HRP20120397T1 (hr) 2012-06-30
CL2009001340A1 (es) 2010-06-04
CA2727825C (fr) 2014-10-21
MY158890A (en) 2016-11-30
TWI451876B (zh) 2014-09-11
JP2012092124A (ja) 2012-05-17
DK2288375T3 (da) 2012-05-21
ES2383496T3 (es) 2012-06-21
NZ588997A (en) 2012-03-30
AU2009257597A8 (en) 2011-01-06
BRPI0915838A2 (pt) 2015-11-03
PE20091960A1 (es) 2010-01-15
ES2473580T3 (es) 2014-07-07
WO2009152128A1 (fr) 2009-12-17
MX2010013837A (es) 2011-05-03

Similar Documents

Publication Publication Date Title
JO2932B1 (en) Lyspro insulin compounds linked to PEG
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
WO2007128817A3 (fr) Dérivé insulinique
WO2007025709A3 (fr) Composes organiques
BR122020010667B8 (pt) inibidores de quinase, seus usos, e composição farmacêutica
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
TR200806298A2 (tr) Farmasötik formülasyon
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
ZA200707973B (en) Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids
MX2009000768A (es) Lactamas macrociclicas.
EA201000141A1 (ru) Новые триазены для лечения рака
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
WO2007076087A3 (fr) Quinazolones d'aryle substitue et leurs utilisations
GB0602951D0 (en) Organic Compounds
WO2008098077A3 (fr) Composés thérapeutiques
WO2012165916A3 (fr) Multimère de polymère sans liaison peptidyle-insuline et procédé pour le produire
MX2009005182A (es) Derivados de 2-hidroxi-1,3-diamino-propano.